Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.200
-0.090 (-6.98%)
At close: Jun 26, 2026, 4:00 PM EDT
1.250
+0.050 (4.17%)
After-hours: Jun 26, 2026, 7:45 PM EDT
Alzamend Neuro Employees
As of April 30, 2025, Alzamend Neuro had 7 total employees, including 4 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,257,455
Market Cap
4.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| PMGC Holdings | 34 |
| GeoVax Labs | 19 |
| Genprex | 13 |
| Processa Pharmaceuticals | 12 |
| Dermata Therapeutics | 9 |
| Enveric Biosciences | 6 |
| Mustang Bio | 4 |
ALZN News
- 2 months ago - Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial - TheFly
- 2 months ago - Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - PRNewsWire
- 3 months ago - Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001 - TheFly
- 3 months ago - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - PRNewsWire
- 3 months ago - Alzamend Neuro Slides: Corporate presentation - Filings
- 3 months ago - Alzamend Neuro initiates Phase II trial of AL001 study - TheFly
- 3 months ago - Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - PRNewsWire
- 3 months ago - Alzamend Neuro Quarterly report: Q3 2026 - Filings